AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects

TheStreet2021-12-10

AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects. He also named it a top pick and ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

VVTZ
2021-12-10
VVTZ
Abbie [Cool]
- MGHuat:
  wow
- Ichua:
  Wow
- VVTZ:
  [Miser]

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1101852117?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-10 13:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101852117","market":"us","top_or_hot":-1,"title":"AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects","media":"TheStreet","content":"<div>\n<p>AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Shares Rise; Wells Fargo Lauds Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 13:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects","article_id":"1101852117","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101852117","pubTimestamp":1639115859,"sourceInfo":null,"weMediaInfo":null,"summary":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of t","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司"},"translate_title":"AbbVie股价上涨；富国银行称赞增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9},"content_text":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and has a $165 share-price target.\nAbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&P 500’s 25% gain.\nWhile many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.\n“Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly (LLY) but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.\nAbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":605357672,"gmtCreate":1639120203620,"gmtModify":1639120203620,"author":{"id":"3582629808245810","authorId":"3582629808245810","name":"VVTZ","avatar":"https://static.tigerbbs.com/2a29e08a133febe21814a6f15264733d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582629808245810","idStr":"3582629808245810"},"htmlText":"Abbie [Cool]&nbsp;","listText":"Abbie [Cool]&nbsp;","text":"Abbie [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/605357672","repostId":1101852117,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6933668,"gmtCreate":1639182600252,"gmtModify":1639182600285,"authorId":3572388238861982,"author":{"id":3572388238861982,"idStr":"3572388238861982","authorId":3572388238861982,"name":"MGHuat","avatar":"https://static.tigerbbs.com/bd2cbc6e014ed9c700e2d9cd01ae2b08","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":605357672,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"},{"id":6925452,"gmtCreate":1639122938874,"gmtModify":1639122938980,"authorId":3554848762875033,"author":{"id":3554848762875033,"idStr":"3554848762875033","authorId":3554848762875033,"name":"Ichua","avatar":"https://static.tigerbbs.com/175ebc8e659de3f491645e9236066d54","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":605357672,"type":1,"supId":0,"prevId":0,"content":"Wow","text":"Wow","html":"Wow"},{"id":6925092,"gmtCreate":1639120239087,"gmtModify":1639120239123,"authorId":3582629808245810,"author":{"id":3582629808245810,"idStr":"3582629808245810","authorId":3582629808245810,"name":"VVTZ","avatar":"https://static.tigerbbs.com/2a29e08a133febe21814a6f15264733d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":605357672,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":18,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101852117"}